期刊
JOURNAL OF VIROLOGY
卷 87, 期 21, 页码 11950-11954出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01672-13
关键词
-
类别
资金
- German Centre for Infection Research (DZIF) [TTU 01.901]
- European Union [223498, 278976]
Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据